Beam, Inc. (BEAM) Tops Q2 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. PTC
2. NVDA
3. PCVX
4. RXO
5. META
6. MSFT
7. SPY
8. GOOGL
9. AMD
10. GMAB

Go back to Beam, Inc. (BEAM) Tops Q2 EPS by 10c

Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results

August 9, 2022 6:30 AM EDT

Patient Enrollment into BEACON Phase 1/2 Trial of BEAM-101 On-track for Second Half of 2022

BEAM-201 IND Submitted to FDA; Currently on Clinical Hold

BEAM-102 IND Submission and BEAM-301 IND-enabling Studies On-track for Second Half of 2022

John Lo, Ph.D., Appointed as Chief Commercial Officer

Ended Second Quarter 2022 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities to Support Advancement of Broad Precision Genetic Medicines Portfolio

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) --... More